Galera Therapeutics Inc
OTC:GRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (34.3), the stock would be worth $0.24 (162% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.1 | $0.09 |
0%
|
| 3-Year Average | 34.3 | $0.24 |
+162%
|
| 5-Year Average | 29.7 | $0.2 |
+127%
|
| Industry Average | 6.9 | $0.05 |
-48%
|
| Country Average | 1.5 | $0.01 |
-89%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Galera Therapeutics Inc
OTC:GRTX
|
13.7m USD | 13.1 | 0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 3.6 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
Galera Therapeutics Inc
Glance View
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Malvern, Pennsylvania and currently employs 30 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The firm's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). The company is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). The company is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The firm is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.
